Next report date
Report period
Q1 2024
EPS estimate
0.52HKD
Revenue estimate
—
2.80HKD
4.48 BHKD
83.06 BHKD
219.90 M
About GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED
Sector
CEO
Hong Li
Headquarters
Guangzhou
Website
Employees (FY)
28.05 K
Founded
1997
ISIN
CNE100000387
FIGI
BBG000BMHD83
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. engages in the manufacture, wholesale, retail, import, and export of pharmaceutical products, medical apparatus, and Chinese medicine. It operates in the following segments: Great Southern Traditional Chinese Medicine (TCM), Great Health, Great Commerce, and Other. The Great Southern TCM segment provides research, development, manufacturing, and sales for Chinese and Western medicine. The Great Health segment refers to the research, development, manufacturing, and sales for the products of Great Health. The Great Commerce segment relates to the wholesale, retail, import, and export for Western medicine, Chinese medicine, and medical apparatus and instruments. The Other segment is involved in other manufacturing and distributing traditional Chinese medicines activities. The company was founded on September 1, 1997 and is headquartered in Guangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 874 is 20.95 HKD — it has increased by 0.24% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange GUANGZHOU BAIYUNSHAN PHARMACEUTICAL stocks are traded under the ticker 874.
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL is going to release the next earnings report on Aug 18, 2024. Keep track of upcoming events with our Earnings Calendar.
874 stock is 2.68% volatile and has beta coefficient of 0.59. Check out the list of the most volatile stocks — is GUANGZHOU BAIYUNSHAN PHARMACEUTICAL there?
874 earnings for the last quarter are 0.18 HKD per share, whereas the estimation was 0.37 HKD resulting in a −52.94% surprise. The estimated earnings for the next quarter are 0.76 HKD per share. See more details about GUANGZHOU BAIYUNSHAN PHARMACEUTICAL earnings.
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL revenue for the last quarter amounts to 19.41 B HKD despite the estimated figure of 23.38 B HKD. In the next quarter revenue is expected to reach 15.15 B HKD.
Yes, you can track GUANGZHOU BAIYUNSHAN PHARMACEUTICAL financials in yearly and quarterly reports right on TradingView.
874 stock has risen by 3.97% compared to the previous week, the month change is a 8.10% rise, over the last year GUANGZHOU BAIYUNSHAN PHARMACEUTICAL has showed a 18.48% decrease.
874 net income for the last quarter is 285.85 M HKD, while the quarter before that showed 1.06 B HKD of net income which accounts for −72.98% change. Track more GUANGZHOU BAIYUNSHAN PHARMACEUTICAL financial stats to get the full picture.
Today GUANGZHOU BAIYUNSHAN PHARMACEUTICAL has the market capitalization of 33.98 B, it has increased by 5.36% over the last week.
Yes, 874 dividends are paid annually. The last dividend per share was 0.81 HKD. As of today, Dividend Yield (TTM)% is 3.89%. Tracking GUANGZHOU BAIYUNSHAN PHARMACEUTICAL dividends might help you take more informed decisions.
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL dividend yield was 3.44% in 2023, and payout ratio reached 27.17%. The year before the numbers were 3.53% and 28.64% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 874 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GUANGZHOU BAIYUNSHAN PHARMACEUTICAL stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 28.05 K employees. See our rating of the largest employees — is GUANGZHOU BAIYUNSHAN PHARMACEUTICAL on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GUANGZHOU BAIYUNSHAN PHARMACEUTICAL technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GUANGZHOU BAIYUNSHAN PHARMACEUTICAL stock shows the sell signal. See more of GUANGZHOU BAIYUNSHAN PHARMACEUTICAL technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on GUANGZHOU BAIYUNSHAN PHARMACEUTICAL future price: according to them, 874 price has a max estimate of 26.13 HKD and a min estimate of 26.04 HKD. Read a more detailed GUANGZHOU BAIYUNSHAN PHARMACEUTICAL forecast: see what analysts think of GUANGZHOU BAIYUNSHAN PHARMACEUTICAL and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL EBITDA is 6.08 B HKD, and current EBITDA margin is 7.23%. See more stats in GUANGZHOU BAIYUNSHAN PHARMACEUTICAL financial statements.